Published in Semin Oncol on December 01, 2010
Parathyroid cancer. Gland Surg (2015) 0.89
Parathyroid carcinoma uncovering the enigma: Case report and review of literature. J Cytol (2011) 0.83
The use of cinacalcet in pregnancy to treat a complex case of parathyroid carcinoma. Endocrinol Diabetes Metab Case Rep (2014) 0.81
Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas. PLoS One (2012) 0.80
Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol (2012) 0.76
Recurrence of Hyperparathyroid Hypercalcemia in a Patient With the HRPT-2 Mutation and a Previous Parathyroid Carcinoma in Hyperparathyroidism-Jaw Tumor Syndrome. Int J Endocrinol Metab (2016) 0.75
Epigenetic Alterations in Parathyroid Cancers. Int J Mol Sci (2017) 0.75
Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight (2017) 0.75
Nonfunctional Metastatic Parathyroid Carcinoma in the Setting of Multiple Endocrine Neoplasia Type 2A Syndrome. Surg Res Pract (2014) 0.75
Decreased expression of calcium-sensing receptor and parafibromin in secondary hyperparathyroidism with an abnormal whole PTH/intact PTH ratio. Clin Kidney J (2013) 0.75
Parathyroid carcinoma: a silent presentation. Gland Surg (2014) 0.75
(18)Fluorocholine PET/CT in parathyroid carcinoma: a new tool for disease staging? Eur J Nucl Med Mol Imaging (2015) 0.75
Non-functioning parathyroid carcinoma: a case report. Surg Case Rep (2017) 0.75
Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab (2001) 5.04
Parathyroid carcinoma. A study of 70 cases. Cancer (1973) 3.44
HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet (2002) 3.07
Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med (2003) 3.07
The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol (2005) 2.58
A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg (2005) 2.56
Cdc73p and Paf1p are found in a novel RNA polymerase II-containing complex distinct from the Srbp-containing holoenzyme. Mol Cell Biol (1997) 2.37
Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet (1999) 2.18
Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med (1994) 1.97
Parathyroid carcinoma: a collective review. Ann Surg (1969) 1.94
Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore) (1992) 1.84
Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. J Clin Endocrinol Metab (2006) 1.79
Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab (2004) 1.75
Dose-response relationships for radiation-induced hyperparathyroidism. J Clin Endocrinol Metab (1995) 1.73
The tumor suppressor Cdc73 functionally associates with CPSF and CstF 3' mRNA processing factors. Proc Natl Acad Sci U S A (2009) 1.70
HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab (2005) 1.70
HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet (2003) 1.69
Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene (2005) 1.56
Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab (1998) 1.56
Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer (2007) 1.52
Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res (2004) 1.47
Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J Surg (1992) 1.46
Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol (2006) 1.40
Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab (2007) 1.39
Parathyroid cancer: biology and management. Surg Oncol (1999) 1.36
Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery (1990) 1.34
Parathyroid carcinoma: a review of 62 patients. Endocr Rev (1982) 1.30
Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer (2007) 1.26
Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer (2010) 1.25
Parathyroid carcinoma. J Bone Miner Res (2008) 1.20
Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer (2007) 1.20
Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg (1992) 1.19
Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg (1985) 1.18
Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg (2001) 1.17
Parafibromin--functional insights. J Intern Med (2009) 1.15
Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J Intern Med (2005) 1.12
Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab (2004) 1.12
Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clin Endocrinol (Oxf) (2006) 1.11
Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol (2007) 1.09
Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet (2004) 1.09
Parathyroid carcinoma: a 22-year experience. Head Neck (2004) 1.08
Surgical resection of metastatic parathyroid carcinoma. Ann Surg (1981) 1.08
Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. Am J Surg Pathol (1999) 1.08
Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr Relat Cancer (2006) 1.08
Cancer-induced hypercalcemia. Anticancer Res (2009) 1.07
Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head Neck Pathol (2009) 1.05
Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer (2009) 1.05
Comparative genomic hybridization analysis of human parathyroid tumors. Cancer Genet Cytogenet (1998) 1.04
Hyperparathyroidism-jaw tumour syndrome. J Intern Med (2003) 1.03
The diagnosis and management of asymptomatic primary hyperparathyroidism. Nat Clin Pract Endocrinol Metab (2006) 1.03
Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene. Oncogene (2006) 1.03
Familial cystic parathyroid adenomatosis. Ann Intern Med (1987) 1.03
Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol (2000) 1.02
Successful combination chemotherapy for metastatic parathyroid carcinoma. Arch Intern Med (1984) 1.01
Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J Bone Miner Res (2006) 1.01
Surgical and medical management of patients with pulmonary metastasis from parathyroid carcinoma. Surgery (1993) 1.00
An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma. Clin Chem (2007) 1.00
The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repression. Nucleic Acids Res (2009) 1.00
Ultrasonographic features of parathyroid carcinoma. Endocr J (2001) 1.00
Parathyroid carcinoma. Curr Treat Options Oncol (2001) 0.99
Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol (2005) 0.97
Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease. World J Surg (1999) 0.97
Implantation of parathyroid carcinoma along fine needle aspiration track. Langenbecks Arch Surg (2006) 0.96
p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab (1994) 0.96
Functional parathyroid carcinoma: Long-term treatment outcome and risk factor analysis. Surgery (2007) 0.96
Cutaneous spreading of parathyroid carcinoma after fine needle aspiration cytology. J Endocrinol Invest (2000) 0.96
Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. Endocr Relat Cancer (2008) 0.94
Parathyroid carcinoma: an overview. Adv Anat Pathol (2005) 0.94
Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab (2008) 0.94
Surgical treatment of ten cases of parathyroid carcinoma: importance of an initial en bloc tumor resection. World J Surg (1984) 0.93
Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res (2004) 0.93
Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol (Oxf) (2007) 0.92
Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas. Int J Oncol (2009) 0.92
Metastatic parathyroid carcinoma in the MEN2A syndrome. Clin Endocrinol (Oxf) (1997) 0.92
Double parathyroid carcinoma. Endocr J (2003) 0.92
Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisis. Mayo Clin Proc (2002) 0.91
Immunoperoxidase study of uncommon parathyroid tumors. Report of two cases of nonfunctioning parathyroid carcinoma and one intrathyroid parathyroid tumor-producing amyloid. Am J Surg Pathol (1983) 0.91
Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J Pathol (2004) 0.91
Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. Clin Endocrinol (Oxf) (2006) 0.90
The tumor suppressor parafibromin is required for posttranscriptional processing of histone mRNA. Mol Carcinog (2010) 0.89
Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery (1984) 0.89
Aberrant methylation of the HRPT2 gene in parathyroid carcinoma. Ann Otol Rhinol Laryngol (2007) 0.89
CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocr Relat Cancer (2010) 0.88
Hyperparathyroidism after neck irradiation. Br J Surg (1988) 0.88
Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab (2004) 0.88
Parathyroid carcinoma in multiple endocrine neoplasia type 1 (MEN1) syndrome: two case reports of an unrecognised entity. J Endocrinol Invest (2007) 0.88
Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol (Oxf) (2003) 0.87
Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Hum Pathol (1995) 0.86
Normocalcemic parathyroid carcinoma: an unusual clinical presentation. World J Surg Oncol (2006) 0.86
Utilisation of a cryptic non-canonical donor splice site of the gene encoding PARAFIBROMIN is associated with familial isolated primary hyperparathyroidism. J Med Genet (2005) 0.86
The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors. Mod Pathol (1997) 0.85
Parathyroid carcinoma in secondary and tertiary hyperparathyroidism. J Am Coll Surg (2004) 0.85
Human chorionic gonadotropin measurements in parathyroid carcinoma. Eur J Endocrinol (2008) 0.84
Nonfunctioning parathyroid carcinoma: case report and review of literature. Endocr Pract (2008) 0.83
Immunohistological study of nonfunctional parathyroid carcinoma. Report of a case. Acta Pathol Jpn (1992) 0.82
Human chorionic gonadotropin subunit measurement in primary hyperparathyroidism. J Clin Endocrinol Metab (1982) 0.82
Dose-response relationship for parathyroid adenoma after exposure to ionizing radiation in infancy. Radiat Res (2002) 0.82
Flow cytometric DNA analysis of parathyroid tumors with special reference to its diagnostic and prognostic value in parathyroid carcinoma. Cancer (1990) 0.81
Resection of pulmonary metastasis from parathyroid carcinoma. Am Surg (2003) 0.81
Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer. N Engl J Med (2015) 5.66
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med (2012) 2.74
American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid (2012) 2.71
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol (2011) 2.49
Should small papillary thyroid cancer be observed? A population-based study. Cancer (2014) 2.21
Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer (2008) 2.09
Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg (2010) 1.70
A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid (2010) 1.68
DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. J Clin Endocrinol Metab (2012) 1.67
Prospective randomized trial of ligasure versus harmonic hemostasis technique in thyroidectomy. Ann Surg Oncol (2010) 1.67
Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations. Arch Surg (2010) 1.66
Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab (2010) 1.57
Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene (2005) 1.56
Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer (2007) 1.52
MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer (2010) 1.51
Reoperation for parathyroid adenoma: a contemporary experience. Surgery (2009) 1.50
Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. Thyroid (2009) 1.41
Should total thyroidectomy become the preferred procedure for surgical management of Graves' disease? Thyroid (2005) 1.40
Predictors of airway complications after thyroidectomy for substernal goiter. Arch Surg (2004) 1.37
Thyroid cancer gender disparity. Future Oncol (2010) 1.36
Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study. Cancer (2011) 1.34
Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid (2010) 1.33
Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg (2010) 1.30
Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metab (2010) 1.27
MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer (2011) 1.26
Accuracy of preoperative localization studies and intraoperative parathyroid hormone assay in patients with primary hyperparathyroidism and double adenoma. J Am Coll Surg (2003) 1.25
The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg (2008) 1.23
The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene. Proc Natl Acad Sci U S A (2008) 1.20
Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch Surg (2008) 1.18
Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg (2006) 1.16
Molecular pathology of the MEN1 gene. Ann N Y Acad Sci (2004) 1.16
Does familial non-medullary thyroid cancer adversely affect survival? World J Surg (2006) 1.15
Are additional localization studies and referral indicated for patients with primary hyperparathyroidism who have negative sestamibi scan results? Arch Surg (2010) 1.12
MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer (2010) 1.11
Thyroidectomy for Hashimoto's thyroiditis: complications and associated cancers. Thyroid (2008) 1.11
Is adrenal venous sampling necessary in all patients with hyperaldosteronism before adrenalectomy? J Vasc Interv Radiol (2008) 1.09
Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery (2004) 1.09
Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function. Mol Cancer Res (2007) 1.07
Impaired cotranslational processing of the calcium-sensing receptor due to signal peptide missense mutations in familial hypocalciuric hypercalcemia. Hum Mol Genet (2005) 1.07
Malignant pheochromocytoma. Surg Oncol Clin N Am (2006) 1.06
Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs. Ann Surg Oncol (2011) 1.05
Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer (2009) 1.05
Recent developments in the clinical application of thyroid cancer biomarkers. Curr Opin Oncol (2008) 1.04
Multivariate analysis of the relationship between male sex, disease-specific survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin. Thyroid (2013) 1.04
Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. Cancer (2010) 1.02
Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors. Mol Endocrinol (2015) 1.01
Knockout of G protein β5 impairs brain development and causes multiple neurologic abnormalities in mice. J Neurochem (2011) 1.01
Laparoscopic adrenalectomy for malignancy. Surg Clin North Am (2004) 1.01
Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J Bone Miner Res (2006) 1.01
Reactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progression. Endocrinology (2012) 1.00
Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res (2002) 1.00
Tumor size predicts malignant potential in Hürthle cell neoplasms of the thyroid. World J Surg (2008) 0.99
Localization of recurrent thyroid cancer using intraoperative ultrasound-guided dye injection. World J Surg (2009) 0.99
Ggamma subunit-selective G protein beta 5 mutant defines regulators of G protein signaling protein binding requirement for nuclear localization. J Biol Chem (2003) 0.99
Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. J Proteome Res (2009) 0.99
Ectopic adrenocorticotropic hormone and corticotropin-releasing hormone co-secreting tumors in children and adolescents causing cushing syndrome: a diagnostic dilemma and how to solve it. J Clin Endocrinol Metab (2015) 0.98
Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation. J Surg Res (2009) 0.98
The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. J Clin Endocrinol Metab (2007) 0.98
Reasons for conversion from laparoscopic to open or hand-assisted adrenalectomy: review of 261 laparoscopic adrenalectomies from 1993 to 2003. World J Surg (2004) 0.97
Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors. J Clin Endocrinol Metab (2003) 0.97
Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocr Rev (2005) 0.97
Hook needle-guided excision of recurrent differentiated thyroid cancer in previously operated neck compartments: a safe technique for small, nonpalpable recurrent disease. J Clin Endocrinol Metab (2006) 0.96
What is the best criterion for the interpretation of adrenal vein sample results in patients with primary hyperaldosteronism? Ann Surg Oncol (2011) 0.95
Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples. Thyroid (2012) 0.95
Defective nucleolar localization and dominant interfering properties of a parafibromin L95P missense mutant causing the hyperparathyroidism-jaw tumor syndrome. Endocr Relat Cancer (2010) 0.95
Patterns of antibiotic prophylaxis use for thyroidectomy and parathyroidectomy: results of an international survey of endocrine surgeons. J Am Coll Surg (2010) 0.95
MiR-886-3p regulates cell proliferation and migration, and is dysregulated in familial non-medullary thyroid cancer. PLoS One (2011) 0.94
Prognostic indications for Hürthle cell cancer. World J Surg (2004) 0.94
Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families. Surgery (2009) 0.93
Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. J Mol Med (Berl) (2014) 0.93
Multiple endocrine neoplasia type 2. Curr Treat Options Oncol (2004) 0.93
Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid. Am J Surg (2010) 0.92
topors, a p53 and topoisomerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage. Oncogene (2005) 0.92
KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer. PLoS One (2011) 0.91
The presence of SDHB mutations should modify surgical indications for carotid body paragangliomas. Ann Surg (2014) 0.91
MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors. Surgery (2013) 0.91
An in vivo mouse model of metastatic human thyroid cancer. Thyroid (2014) 0.90
Use of the electrothermal vessel sealing system versus standard vessel ligation in thyroidectomy. Asian J Surg (2005) 0.90
Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J Clin Endocrinol Metab (2004) 0.90
Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype. J Clin Endocrinol Metab (2013) 0.90
Summary statement: utility of molecular marker testing in thyroid cancer. Surgery (2010) 0.90
Selective use of steroid replacement after adrenalectomy: lessons from 331 consecutive cases. Arch Surg (2006) 0.89
Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells. Surgery (2005) 0.89
TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer (2013) 0.89
Utility of rapid intraoperative parathyroid hormone assay to predict severe postoperative hypocalcemia after reoperation for hyperparathyroidism. Surgery (2002) 0.89
A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy. Surgery (2010) 0.89
Rate of clinically significant postoperative pancreatic fistula in pancreatic neuroendocrine tumors. World J Surg (2012) 0.88
Nuclear localization of the G protein beta 5/R7-regulator of G protein signaling protein complex is dependent on R7 binding protein. J Neurochem (2010) 0.88
Does the presence of additional thyroid nodules on ultrasound alter the risk of malignancy in patients with a follicular neoplasm of the thyroid? Surgery (2007) 0.88
Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing. J Clin Endocrinol Metab (2011) 0.87
Identification of differentially expressed microRNA in parathyroid tumors. Ann Surg Oncol (2010) 0.87
Does the 3-gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms? Cancer (2008) 0.86
Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted? J Am Coll Surg (2013) 0.86
Association of type O blood with pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome. Ann Surg Oncol (2012) 0.86
Integrated analysis of genome-wide methylation and gene expression shows epigenetic regulation of CYP11B2 in aldosteronomas. J Clin Endocrinol Metab (2013) 0.85
Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers. Surgery (2008) 0.85
Does routine consultation of thyroid fine-needle aspiration cytology change surgical management? J Am Coll Surg (2007) 0.85
Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. Surgery (2011) 0.84